Mega Lifesciences Public Company Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
August 11, 2023 at 06:21 am EDT
Share
Mega Lifesciences Public Company Limited reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported revenue was THB 3,978.03 million compared to THB 1,662.63 million a year ago. Net income was THB 530.95 million compared to THB 569.51 million a year ago. Basic earnings per share from continuing operations was THB 0.61 compared to THB 0.65 a year ago.
For the six months, revenue was THB 7,757.22 million compared to THB 7,798.75 million a year ago. Net income was THB 983.94 million compared to THB 1,183.51 million a year ago. Basic earnings per share from continuing operations was THB 1.13 compared to THB 1.36 a year ago.
Mega Lifesciences Public Company Limited is engaged in manufacturing, marketing, selling and distributing quality pharmaceutical, nutraceutical products and Fast-Moving Consumer Goods (FMCG). Its segments include Maxxcare distribution business, Mega We Care branded products business, and original equipment manufacturer (OEM) business. The Maxxcare distribution business markets, sells and distributes various branded prescription pharmaceutical products, OTC and FMCG products. Its services include warehouse management, collections, including assuming the liability for bad debts, and value-added services. Its Mega We Care branded products business develops, manufactures, markets and sells its own brand of nutraceutical products, prescription pharmaceutical products and OTC products. Mega We Care branded products are sold in a total of 35 countries around the world. Its manufacturing facilities in Thailand and Australia accept various production orders from third-party customers.